288 related articles for article (PubMed ID: 32751699)
1. Targeting Multiple Myeloma through the Biology of Long-Lived Plasma Cells.
Utley A; Lipchick B; Lee KP; Nikiforov MA
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751699
[TBL] [Abstract][Full Text] [Related]
2. Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle.
Lightman SM; Utley A; Lee KP
Front Immunol; 2019; 10():965. PubMed ID: 31130955
[TBL] [Abstract][Full Text] [Related]
3. Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells.
Nguyen DC; Joyner CJ; Sanz I; Lee FE
Front Immunol; 2019; 10():2138. PubMed ID: 31572364
[TBL] [Abstract][Full Text] [Related]
4. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells.
Rozanski CH; Arens R; Carlson LM; Nair J; Boise LH; Chanan-Khan AA; Schoenberger SP; Lee KP
J Exp Med; 2011 Jul; 208(7):1435-46. PubMed ID: 21690252
[TBL] [Abstract][Full Text] [Related]
5. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
6. The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA Vaccination.
Nguyen DC; Hentenaar IT; Morrison-Porter A; Solano D; Haddad NS; Castrillon C; Lamothe PA; Andrews J; Roberts D; Lonial S; Sanz I; Lee FE
medRxiv; 2024 Mar; ():. PubMed ID: 38496525
[TBL] [Abstract][Full Text] [Related]
7. The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA Vaccination.
Lee F; Nguyen D; Hentenaar I; Morrison-Porter A; Solano D; Haddad N; Castrillon C; Lamothe P; Andrews J; Roberts D; Lonial S; Sanz I
Res Sq; 2024 Mar; ():. PubMed ID: 38559048
[TBL] [Abstract][Full Text] [Related]
8. Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells.
Staupe RP; Lodge KE; Thambi N; Toole D; Tamburino AM; Chang D; Howell BJ; Hazuda DJ; Vora KA; Sullivan NL
Commun Biol; 2022 Dec; 5(1):1399. PubMed ID: 36543997
[TBL] [Abstract][Full Text] [Related]
9. Plasma cell survival: The intrinsic drivers, migratory signals, and extrinsic regulators.
Nguyen DC; Duan M; Ali M; Ley A; Sanz I; Lee FE
Immunol Rev; 2021 Sep; 303(1):138-153. PubMed ID: 34337772
[TBL] [Abstract][Full Text] [Related]
10. Autophagy and the Bone Marrow Microenvironment: A Review of Protective Factors in the Development and Maintenance of Multiple Myeloma.
Hamedi KR; Harmon KA; Goodwin RL; Arce S
Front Immunol; 2022; 13():889954. PubMed ID: 35663979
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
12. Progressive differentiation toward the long-lived plasma cell compartment in the bone marrow.
Koike T; Fujii K; Kometani K; Butler NS; Funakoshi K; Yari S; Kikuta J; Ishii M; Kurosaki T; Ise W
J Exp Med; 2023 Feb; 220(2):. PubMed ID: 36515679
[TBL] [Abstract][Full Text] [Related]
13. Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival culture.
Nguyen DC; Saney C; Hentenaar IT; Cabrera-Mora M; Capric V; Woodruff MC; Andrews J; Lonial S; Sanz I; Lee FE
Sci Rep; 2024 Feb; 14(1):3616. PubMed ID: 38350990
[TBL] [Abstract][Full Text] [Related]
14. Majority of human circulating plasmablasts stop blasting: A probable misnomer.
Nguyen DC; Saney C; Hentenaar IT; Cabrera-Mora M; Woodruff MC; Andrews J; Lonial S; Sanz I; Lee FE
bioRxiv; 2023 Sep; ():. PubMed ID: 37745615
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
16. Autophagy-related mechanisms for treatment of multiple myeloma.
Kozalak G; Koşar A
Cancer Drug Resist; 2023; 6():838-857. PubMed ID: 38239705
[TBL] [Abstract][Full Text] [Related]
17. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
18. Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses.
Duan M; Nguyen DC; Joyner CJ; Saney CL; Tipton CM; Andrews J; Lonial S; Kim C; Hentenaar I; Kosters A; Ghosn E; Jackson A; Knechtle S; Maruthamuthu S; Chandran S; Martin T; Rajalingam R; Vincenti F; Breeden C; Sanz I; Gibson G; Eun-Hyung Lee F
bioRxiv; 2023 Jan; ():. PubMed ID: 36711623
[TBL] [Abstract][Full Text] [Related]
19. SLE Antibody-Secreting Cells Are Characterized by Enhanced Peripheral Maturation and Survival Programs.
Chen W; Hong SH; Jenks SA; Anam FA; Tipton CM; Woodruff MC; Hom JR; Cashman KS; Faliti CE; Wang X; Kyu S; Wei C; Scharer CD; Mi T; Hicks S; Hartson L; Nguyen DC; Khosroshahi A; Lee S; Wang Y; Bugrovsky R; Ishii Y; Lee FE; Sanz I
Res Sq; 2023 Jun; ():. PubMed ID: 37461641
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
